New form of existing wake-promoting drug approved

Article

The FDA has given the go-ahead to Cephalon Inc. to market armodafinil (Nuvigil) for the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome, narcolepsy, and shift-work sleep disorder.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.